The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract titled "Early Phase Clinical Trial Units (EPCTU)" to Icon Government And Public Health Solutions, Inc., a foreign-owned, for-profit organization. The $346.6 million IDIQ will support Phase 0 through Phase II clinical trials of investigational products against infectious diseases over a 10-year period ending in January 2032.
Two task orders have been issued under this IDIQ. The first, valued at $2,021,154, covers Phase I healthy volunteer studies and Phase I special population studies. The second, valued at $1,628,393, also supports early-phase clinical trial activities over the 10-year period of performance. Icon, which specializes in comprehensive clinical trial services, will perform the work at its facility in Hinckley, Ohio. This IDIQ contract does not utilize any set-aside designations.
Generated 11/21/24, 9:07 AM